Alvotech Expands Board of Directors Following Transition to Public Company
Biotechnology firm Alvotech has expanded its board of directors with four new members as it transitions from a private entity to a publicly traded company. The expansion strengthens the company's governance post-listing.
Biotechnology firm Alvotech announced the expansion of its board of directors with the addition of four new members. This move coincides with the company's transition from a private company to a publicly traded entity.
The newly appointed directors are Lisa Graver, Arni Hardarson, Linda McGoldrick, and Ann Merchant. They join existing members including founder and Executive Chairman Robert Wessman. Alvotech completed its listing on the Nasdaq stock exchange in New York on June 16, 2022, followed by its listing on the Nasdaq First North Growth Market in Iceland on June 23, 2022.
Alvotech specializes in the development and manufacture of biosimilar medicines, aiming to enhance global access to biologic treatments. Robert Wessman, Executive Chairman and founder, stated that the scientific expertise, operational experience, and capital markets acumen of the new directors will be important in supporting the company's mission.
The expanded board is expected to provide crucial governance and strategic guidance as Alvotech continues its growth trajectory in the global biosimilars market, focusing on increasing patient access to affordable biologic medicines.